Mark A. Glickman - 06 Dec 2022 Form 4 Insider Report for TherapeuticsMD, Inc. (TXMD)

Reporting relationship: Co-Chief Executive Officer
Issuer ticker: TXMD
Reported as of: 06 Dec 2022
Net transaction value: -$2,165
SEC form: 4
Accepted by SEC: 09 Dec 2022, 18:38:08 UTC
Prior SEC filing: 31 Mar 2022
Next SEC filing: 12 May 2023
Source filing: View source filing
Reporting owner signature: /s/ Mark A. Glickman

Key filing fact

Mark A. Glickman filed Form 4 for TherapeuticsMD, Inc. (TXMD) on 09 Dec 2022.

Key facts

This page summarizes Mark A. Glickman's Form 4 filing for TherapeuticsMD, Inc. (TXMD).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 09 Dec 2022, 18:38.

Change

Previous filing in this sequence was filed on 31 Mar 2022.
Current net transaction value: -$2,165.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TXMD transaction

Common Stock

Options Exercise

Transaction value: $0
Shares: +1,734
Change %
Price: $0.000000
Shares after: 1,734
Date: 06 Dec 2022
Ownership: Direct
Footnotes: F1

TXMD transaction

Common Stock

Sale

Transaction value: $2,165
Shares: -440
Change %: -25%
Price: $4.92
Shares after: 1,294
Date: 06 Dec 2022
Ownership: Direct
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TXMD transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value: $0
Shares: -1,734
Change %: -33%
Price: $0.000000
Shares after: 3,466
Date: 06 Dec 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,734
Exercise price: $0.000000
Footnotes: F1, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On December 6, 2022, the reporting person received 1,734 shares of issuer common stock in settlement of restricted stock units (RSUs).

Footnote F2

The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations

Footnote F3

The RSUs will vest in three equal installments annually beginning October 15, 2022, becoming fully vested on October 15, 2024, subject in each case to the continued service of the reporting person with the issuer.